



South West Regional Transfusion Committee

# When to challenge requests for blood components – and why

## Janet Birchall Consultant Haematologist NHSBlood & Transplant/ North Bristol NHSTrust

# Why question **?**

- Appropriate use
- Safety



- -Longer term outcome
- Shortage
- Cost

# Mortality and morbidity in patients with very low postoperative Hb levels

Hb level (g/dl)	% mortality	% mortality/morbidity
1.1 - 2.0	100%	100%
2.1 - 3.0	54.2%	91.7%
3.1 - 4.0	25%	52.6%
4.1 - 5.0	34.4%	57.7%
5.1 - 6.0	9.3%	28.6%
6.1 - 7.0	8.9%	22%
7.1 - 8.0	0%	9.4%

Odds of death in patients with post-op Hb <8 g/dl increased 2.5 fold for each gram decrease in Hb. (Transfusion 2002, 42, 812-818)

### **2011 Medical Use of Blood Audit** Inappropriate transfusion - National 13%, NBT 9%

### **Iron deficiency**

Parameter	Men	Women
Total number	4791	4335
With ferritin result (%)	1774 (37%)	1725 (40%)
With ferritin $\leq$ 20 mcg/l (male) or $\leq$ 15 mcg/l (female)	248	341
With transferrin saturation $\leq$ 20 in cases without ferritin results	58	78
With MCV $\leq$ 78 fl in cases without ferritin or iron studies	210	264
Total possible iron deficiency	516	683

### **Overall 13% of all patients transfused**

In NBT at least 13% transfused with iron deficiency

### Management of anaemia and avoidance of Transfusion. Audit in NI February 2010 743 transfusion episodes audited. 1 in 4 could have been avoided.

Iron deficiency most common cause of correctable anaemia



### National comparative audit of platelet transfusions 2010

### Key Findings of the audit with regard to the inappropriate use of platelet transfusions

- The audit found 28% (915/3296) inappropriate use of platelet transfusions using algorithms for defining appropriateness based on the most recent BCSH guidelines for platelet transfusions. Inappropriate transfusions were mostly because of prophylactic platelet transfusions above the recommended thresholds and the use of platelet transfusions for procedures such as bone marrow aspirate/trephine which can be safely conducted without platelet cover.<sup>1</sup>
- 2. The majority, 69% (2283/3296) of the platelet transfusions, were prophylactic and 34% (782/2283) of these were considered to be inappropriate, mostly 26% (602/2283) because of transfusion above the recommended platelet count threshold but also 8% (180/2283) were administered as prophylactic transfusions to patients with myelodysplastic syndrome (MDS) who did not have additional risk factors for bleeding. An additional 6% (126/2283) were indeterminate because no recent platelet count had been performed and possibly inappropriate.
- 3. 10% (220/2277) of prophylactic platelet transfusions were double-dose transfusions (in 6 cases the dose was not reported). The majority, 73% (161/220) of double-dose transfusions, were administered to inpatients. A recent large randomised controlled trial has shown no difference in the number of patients who had significant bleeding (WHO grade 2 or above) when they received single or double-dose platelet transfusions.<sup>2</sup>




Risk of major morbidity and mortality per 1,000,000 components issued in 2013	
Total morbidity	51.8
Total mortality	8.0

	Mortality	Major morbidity	Total cases
All errors	2.2	5.1	346.2
Acute transfusion reactions	0.0	27.6	116.0
Haemolytic transfusion reactions	0.4	2.9	17.8
Transfusion-related acute lung injury	0.4	3.3	3.6
Transfusion-associated circulatory overload	4.4	12.3	34.8
Transfusion-associated dyspnoea	0.0	0.4	2.2
Transfusion-associated graft versus host disease	0.0	0.0	0.0
Post-transfusion purpura	0.4	0.0	1.1
Cell salvage	0.0	0.0	4.4
Transfusion-transmitted infection	0.0	0.0	0.0
Unclassifiable complications of transfusion	0.4	0.4	2.2
Paediatric cases	0.7	1.5	37.0

# Mortality, morbidity & transfusion

**Transfusion Triggers in Critically ill Patients** NEJM. 1999;340:409-417 Randomised to trigger Hb 7 or 10 g/dl. No difference in 1°outcome - death 30 days. Trend towards  $\downarrow$  30-day mortality in restrictive arm

Liberal or Restrictive Transfusion in High-Risk Patients after Hip Surgery Carson JL, NEJM 2011;365:2453-62 Randomised prospective, n = 2016, > 50 with CVD/risk factors. < 10g/dl v < 8g/dl No difference in 1°outcome - death or inability to walk 10 feet unaided at 60 days



### **2014 Low stocks**

### Red cells March

Platelets August October November

#### **NHS** Blood and Transplant

#### URGENT COMMUNICATION

An electronic copy of this fax can be found on the Hospitals & Science "Home Page" via the urgent area highlighted in red - <u>http://hospital.blood.co.uk/</u>.

#### 25<sup>th</sup> March 2014

All Transfusion Laboratory Managers in hospitals served by NHS Blood and Transplant

#### Dear Colleague,

Update on Stocks of B RhD Negative and O RhD Negative Red Cells

On the 12<sup>th</sup> and 19<sup>th</sup> March we advised you that NHSBT were experiencing lower than normal levels of groups O RhD negative and B RhD negative red cells

Stock levels have increased and we have returned to business as usual and are able to supply to your needs.

We would like to thank you for your assistance and understanding whilst we rebuilt our stock levels.

If you have any queries regarding the above, please do not hesitate to contact an NHSBT Customer Service Manager, Hospital Services Manager or NHSBT Consultant. Alternatively please contact the Customer Service Response Desk on - 0208 201 3107 between the hours of 9:00 to 17:00, Monday to Friday.

Please also notify your Consultant with responsibility for the transfusion laboratory and your Transfusion Practitioner of this communication.

Yours sincerely,

Teresa Allen

Teresa Allen Assistant Director - Customer Service Email: teresa.allen@nhsbt.nhs.uk

R.L C

Prof. Mike Murphy Clinical Director – Patients Email: <u>mike.murphy@nhsbt.nhs.uk</u>

# **Contingency Plan for Shortage**

Category 1	Category 2	Category 3
Active major bleeding	Cancer surgery (palliative) Urgent but not emergency surgery	Elective surgery, likely to require Tx
Emergency surgery	Not life threatening anaemia	
Life threatening anaemia		

#### Price List 2013/2014

#### **NHS** Blood and Transplant

NHS

#### **Blood and Components**

#### Red Cell Components / Supplements

Item Code	Item Description	Price £ 2013/2014
N12	Standard Red Cells	£ 122.09
N13	Neonatal Red Cells	£ 48.38
N14	Frozen Red Cells, Thawed & Washed	£ 420.20
N15	Red Cells for Exchange Transfusion	£ 184.60
N16	Red Cells for Intrauterine Transfusion	£ 168.64
N18	Red Cells- Large Volume Neonates/Infants	£ 146.32
N21	Premium for CMV -ve Red Cells	£ 8.38
N22	Premium for Irradiated Red Cells	£ 8.36
N23	Premium for Cell Washing	£ 115.94
N29	Discounted Cell Washing (24 Hour)	£ 30.14

#### Platelet Components / Supplements

Item Code	Item Description	Price £ 2013/2014
N31	Neonatal Platelets	£ 89.16
N32	Platelets (1.0 ATD)	£ 208.09
N34	Platelets for IUT	£ 316.00
N39	Buffy Coats	£ 67.23
N41	Premium for CMV -ve Platelets	£ 8.38
N42	Premium for Irradiated Platelets	£ 8.36
N43	Premium for HLA Selected Platelets	£ 180.09
N44	Premium for HPA Selected Platelets	£ 180.09
N45	Premium for Cell Washing/Additive Soluti	£ 31.78
	Optimised Pooled Granulocyte	£ 1,041.10

#### Plasma Components

Item Code	Item Description	Price £ 2013/2014
N51	Clinical FFP (UK sourced)	£ 27.98
N53	Cryo-depleted Plasma	P.O.R
N54	Cryoprecipitate	£ 31.70
N58	Paediatric MBFFP (Non UK Sourced)	£ 177.01
N59	Neonatal MBFFP (Non UK Sourced)	£ 49.75
N5A	Pooled Cryoprecipitate	£ 193.53
N5C	MB Cryoprecipitate Neonatal (Non UK )	£ 137.49

# **Patient Blood Management**

- Aim to achieve better patient outcome by relying on patients own blood rather than donor blood
- Goes beyond appropriate use as pre-empts and ↓ need for donor blood by addressing modifiable risk factors
  - Maximise patients red cell mass
  - Minimise bleeding
  - Optimise patients physiological reserve

# National Blood Transfusion Committee Indication Codes for Transfusion 2013

"The indications for transfusion taken from UK national guidelines for the use of blood components. Although clinical judgment plays an essential part in the decision to transfuse, the purpose of drawing available transfusion guidelines together into one short document is to help clinicians decide when blood transfusion is appropriate and to facilitate documentation of the indication "

### NHS

THE REPORT

< mm .....

Ö

STREET THE PARTY

The Chief Medical Officer's National Blood Transfusion Committee Issued 11/11

#### Indication Codes for Transfusion – an Audit Tool

The indications for transfusion provided below are taken from UK national guidelines for the use of blood components (see references). Although it is accepted that clinical judgement plays an essential part in the decision to transfuse or not, the purpose of drawing available transfusion guidelines together into one short document is to help clinicians decide when blood transfusion is appropriate and to facilitate documentation of the indication for transfusion. Each indication has been assigned a number, which may be used by clinicians when requesting blood or for documentation purposes. Specific details regarding the patient's diagnosis and any relevant procedures to be undertaken should also be provided. These are current guidelines and may change depending on new evidence.

7.00000 1110

#### Red cell concentrates

#### R1 Acute blood loss 4.8.3

In patients with haemorrhage, the haemoglobin concentration (Hb) is a poor indicator of acute blood loss and estimation of blood loss may be difficult. Empirical decisions about the immediate use of red cell transfusion are required by clinicians experienced in rescuscitation. The following is a guide to the likelihood of the need for blood transfusion:

- < 30% loss of blood volume (< 1500ml in an adult): transfuse crystalloid/colloid. Red cell transfusion is unlikely to be necessary.
- 30-40% loss of blood volume (1500-2000ml in an adult): rapid volume replacemen is required with crystalloid/colloid. Red cell transfusion will probably be required to maintain recommended Hb levels
- >40% loss of blood volume (>2000ml in an adult): rapid volume replacement including red cell transfusion is required.

When normovolaemia has been achieved/maintained. when normovolaema has been achievedmaintained, frequent measurement of Hb (for example, by near patient testing) can be used to guide the use of red cell transfusion. Maintain circulating blood volume and Hb >7 g/di in otherwise fit patients, and >8g/di in eiderly patients and those with known cardiovarcular disease

#### Peri-operative transfusion 2,4

Many patients undergoing elective surgical operations will not require transfusion support if their Hb is normal before surgery. Assuming normovolaemia has been maintained, the Hb can be used to guide the use of red cell transfusion

#### R2. Hb <7a/dl

R3. Hb <8g/dl in a patient with known cardiovascular disease, or those with significant risk factors for cardiovascular disease (e.g. elderly patients, and those with hypertension, diabetes mellitus, peripheral vascular

#### Critical Care

R4. Transfuse to maintain the Hb >7g/dl, and >8g/dl in elderly patients and those with known cardiovascular disease

#### Post-chemotherapy

R5. There is no evidence-base to guide practice. Most hospitals use a transfusion threshold of a Hb of 8 or 9g/dl.

#### Radiotherapy

R6. Limited evidence for maintaining Hb above 10-11g/dl in patients receiving radiotherapy for cervical and possibly other tumours.

#### Chronic anaemia 4

R7. Transfuse to maintain the haemoglobin concentration to prevent symptoms of anaemia. Many patients with chronic anaemia may be asymptomatic with a Hb >8a/dl.

#### Fresh frozen plasma 6.3

(Dose - 12 - 15ml/kg body weight equivalent to 4 units for an adult)

- F1. Replacement of single coagulation factor deficiencies, where a specific or combined factor concentrate is unavailable e.g. factor V.
- F2. Immediate reversal of warfarin effect, in the presence concentrate is the treatment of choice. FFP only has a partial effect and is not the optimal treatment. NICESS. And A CONTRACTOR OF THE PARTY O
- F3. Acute disseminated intravascular coagulation (DIC) in the presence of bleeding and abnormal coagulation results
- F4. Thrombotic thrombocytopenic purpura (TTP), usually in conjunction with plasma exchange

### of of fairwareareau and fairwareareau and fairwareareau and fairwareau and fairwa

F5. Massive transfusion. If emergency uncontrolled bleeding and massive haemorrhage is anticipated, early influsion of FFP (15milkg) is recommended to treat coagulopathy, Local protocols should be followed, and the later use of FFP should be guided by timely tests of coagulation including near patient testing. Where there is anticipated large volume blood loss associated with routine surgery, guidelines suggest the PT and APTT ratio should be maintained at <1.5. This is likely to occur after replacement of 1-1.5 x the patient's blood volume.

F6. Liver disease; there is no evidence of benefit from FFP in atients with a PT ratio of less than or equal to 1.5.

#### Cryoprecipitate 6,3

- (Dose 2 pooled units, equivalent to 10 individual donor units, for an adult (contains approximately 3g of fibrinogen ) Cryoprecipitate should be used in combination with FFP unless there is an isolated deficiency of fibrinogen. BELLEVILLE
- C1. Acute disseminated intravascular coagulation (DIC), where there is bleeding and a fibrinogen level <1g/l.</p> C2. Advanced liver disease, to correct bleeding or as prophylaxis before surgery, when the fibrinogen level <1g/l.
- C3. Bleeding associated with thrombolytic therapy causing ofibrinogenaemia.
- C4. Hypofibrinogenaemia secondary to massive transfusion. Maintain fibrinogen above 1g/l. A level of 1.5g/l may be required CS. Renal failure or liver failure associated with abnormal bleeding where DDAVP is intraindicated or ineffectiv
- C6. Inherited hypofibrinogenaemia, where fibrinogen concentrate is not readily available

#### Platelet concentrates 1,3,5,7

(Dose - 15 ml/kg body weight for children <20kg; 1 adult therapeutic dose for adults and older children

#### Rone marrow failure

- P1. To prevent spontaneous bleeding in patients with reversible bone marrow failure when the platelet count <10 x 10 %. Prophylactic platelet transfusions are not indicated in chronic stable thrombocytopenia.
- P2. To prevent spontaneous bleeding when the platelet count <20 x 10<sup>9</sup>/l in the presence of additional risk factors for bleeding such as sepsis or haemostat abnormalities
- P3. To prevent bleeding associated with invasive procedures. The platelet count should be raised to >50 x 10<sup>4</sup>/b efore lumbar puncture, insertion of intravascular lines, transbronchia and liver blopsy, and laparotomy; to >80 x 10<sup>4</sup>/b efore spinal epidural anaesthesia and to >100 x 10<sup>4</sup>/b lefore surgery in critical sites such as the brain or

- Critical care/surgery P4. Massive blood transfusion. Empirical use of platelets, according to a specific blood component ratio, is reserved for the patients, with severe trauma. Aim to maintain platelet count >75 x 10<sup>-/1</sup> and >100 x 10<sup>-/1</sup> if multiple, eye or CNS trauma.
- P5. Acquired platelet dysfunction e.g. post-cardiopulmonary bypass, use of potent anti-platelet agents such as clopidigrel, with non surgically correctable bleeding.
- P6. Acute disseminated intravascular coagulation (DIC) in the presence of bleeding and severe thrombocytopenia.
- P7. Inherited platelet dysfunction disorders e.g. Glanzmanns thrombasthenia with bleeding or as prophylaxis before surgery.

#### Immune thrombocytopenia P8. Primary immune thrombocytopenia, as emergency

- transmittin advance of surgery or in the presence of major haemorrhage. A platelet count of  $\geq 80$  is recommended for major surgery and a count of  $>70 \times 10^9$ /l for obstetric regional axial anaesthesia
- P9. Post-transfusion purpura, in the presence of major haemorrhage.
- P10. Neonatal alloimmune thrombocytopenia, to treat bleeding or as prophylaxis to maintain the platelet count >30 x 10<sup>9</sup>/l.

#### recently updated indication code ards in Haematology (2004a). Guidelines for the use of fresh-frozen plasma, cryptecipitate and cryosupernatant. British waematology; 126, 11-28. aematology (2804b). Transfusion guidelines for neonates and older children. British Journal of

#### 41-63. 8 Sottish Intercolegate Gubbines Retwork (2009). Management of upper and lower gest-contestinal Meeting (www.sign.ac.at). Poolescor Mitte Marphy Dr Jonathan Vialiti, Dr Janet Brchall, October 2011

### **NBTC Indication codes (triggers) Poster & Bookmark**

#### NHS

#### National Blood Transfusion Committee

#### Guidance for the use of Blood Components

This guidance is based on the NBTC Indication Codes for Transfusion (April 2013).

#### Red Cell Concentrates

#### Consider single unit only transfusion if anaemia reversible.

 R1 Acute blood loss in an emergency. Hb unreliable, resuscitation by experienced clinician, transfuse if blood loss >30%. When normovolaemic use Hb thresholds below.

#### Surgery/medical/critical care

- R2 Use Hb of <70 o/l as a guide for red cell transfusion.</li> R3 Cardiovascular disease – consider transfusion at Hb <80g/l or for symptoms e.g. chest pain; hypotension
- or tachycardia unresponsive to fluid resuscitation: or cardiac failure.
- R4 Severe sepsis, traumatic brain injury and/or acute cerebral ischaemia - use Hb <90g/l to guide transfusion.
- R5 Radiotherapy Limited evidence for maintaining Hb >100a/l.
- · R6 Chronic anaemia Maintain Hb to prevent symptoms of anaemia. Hb >80g/l appropriate for many patients.
- R7 Exchange transfusion.

#### FFP (15ml/kg)

- F1 Coaculation factor deficiency where factor concentrate unavailable.
- F2 Reversal of warfarin if critical bleeding. Prothrombin complex concentrate is the treatment of choice
- F3 Disseminated intravascular coagulation (DIC) if bleeding and abnormal coagulation.
- F4 Thrombotic thrombocytopenic purpura.
- F5 Major haemorrhage if emergency uncontrolled bleeding, early infusion of FFP recommended. Subsequent use to maintain PT/APTT ratio <1.5 and fibrinogen >1.5g/l (see also C4).
- F6 Liver disease (non-bleeding): no evidence of benefit for FFP, regardless of PT ratio.

#### Reference:

National Blood Transfusion Committee Indication Codes – An Audit Tool (April 2013) http://www.transfusionguidelines.org/docs/pdfs/ nbtc\_2014\_04\_recs\_indication\_codes\_2013.pdf

PTO

#### NHS

#### National Blood Transfusion Committee

Platelet concentrate (1 unit = 1 adult therapeutic dose or ATD)

#### Bone marrow failure (BMF)

- P1 Prophylactic use if reversible BMF and count <10 x10%. Not indicated in chronic stable BMF.
- P2 Prophylactic use if BMF with additional risk factors for bleeding e.g. sepsis if count <20 x 10%.
- P3 invasive procedure keep count >50 x10%, >80 x10% If epidural, >100 x10% If CNS or eye surgery. Transfusion prior to bone marrow biopsy is not usually required.

#### Critical care

- P4 Massive transfusion aim for count of >75 x10<sup>9</sup>/l, >100 x10<sup>9</sup>/1 if multiple, CNS or eve trauma.
- P5 Acquired platelet dysfunction if non-surgically correctable bleeding.
- P6 Acute DIC and bleeding with severe thrombocytopaenia.
- P7 Inherited platelet dysfunction with bleeding or pre-surgery.

#### Immune thrombocytopenia

fibrinogen <1 g/l.

hypofibrinogenaemia.

DDAVP not appropriate.

transfusion laboratory.

available.

August 2013

BLC675.1

- P8 Immune thrombocytopenia as emergency pre-surgery or with haemorrhage. Aim for count >80 x10% pre-major surgery and >70 x10% for obstetric regional axial anaesthesia.
- P9 Post-transfusion purpura if major haemorrhage.
- P10 Neonatal alloimmune thrombocytopenia maintain count >30 x10%

#### Cryoprecipitate. Use with FFP unless isolated fibrinogen deficiency (2 pooled units for an adult)

C1 DIC and bleeding when fibrinogen <1g/l.</li>

C2 Liver disease with bleeding or pre-surgery when

C3 Bleeding with thrombolytic therapy causing

Further information on blood transfusion will be


available on hospital intranet sites or from the blood

1314208

C4 Massive transfusion maintain fibrinogen >1.5g/l.

C5 Renal or liver failure with abnormal bleeding when

C6 Inherited hypofibrinogenaemia when concentrate not



# Summary

Discuss unclear requests for reasons of -

- Appropriate use
- Safety short and long term
- Potential shortage
- Cost
- Use National Blood Transfusion Committee Indication Codes and South West RTC laboratory algorithm as part of PBM